Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster

Although the anti-CD20 antibody Rituximab has revolutionized the treatment of Non-Hodgkin Lymphoma (NHL), resistance to treatment still existed. Thus, strategies for suppressing Rituximab-resistant NHLs are urgently needed. Here, an anti-CD20 nanocluster (ACNC) is successfully constructed from its t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huafei, Zhang, Ge, Jiang, Cheng, Zhang, Fulei, Ke, Changhong, Zhao, He, Sun, Yun, Zhao, Mengxin, Chen, Di, Zhu, Xiandi, Zhang, Li, Li, Bohua, Dai, Jianxin, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695179/
https://www.ncbi.nlm.nih.gov/pubmed/26284588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695179/
https://www.ncbi.nlm.nih.gov/pubmed/26284588

Ejemplares similares